Abstract Number: 2847 • 2018 ACR/ARHP Annual Meeting
Associations between Serum Uric Acid Level and Coronary Artery Disease
Title: Association between Serum Uric Acid Level and Coronary Artery DiseaseBackground/Purpose: Previous studies have shown an unclear relationship between serum uric acid (SUA) and coronary…Abstract Number: 2848 • 2018 ACR/ARHP Annual Meeting
Racial Disparities in Utilization of Knee Replacement: Data from the Osteoarthritis Initiative
Background/Purpose: While risk of knee osteoarthritis (OA) is higher among black than white individuals, the rate of knee replacement—an effective treatment for end-stage OA among…Abstract Number: 2849 • 2018 ACR/ARHP Annual Meeting
Risk of Obstructive Sleep Apnea in Rheumatoid Arthritis
Background/Purpose: Self-reported sleep disturbances (SDs) are common in RA. Most studies of sleep in RA have focused on SDs in general. Obstructive sleep apnea (OSA)…Abstract Number: 2850 • 2018 ACR/ARHP Annual Meeting
Human Toll-like Receptor 8 Adversely Affects Placental Development and Pregnancy Outcomes in a Mouse Model of Systemic Lupus Erythematosus
Background/Purpose: Systemic Lupus Erythematosus (SLE) predominantly affects women of childbearing age and is associated with adverse pregnancy outcomes including pre-eclampsia, intrauterine fetal growth restriction (IUGR),…Abstract Number: 2851 • 2018 ACR/ARHP Annual Meeting
NF-Κappa b Signaling in the Myeloid Cell Lineage Drives the Pathogenesis of Immune-Mediated Nephritis
Background/Purpose: Immune-mediated glomerulonephritis is a serious end organ pathology that commonly affects patients with systemic lupus erythematosus (SLE). Nephrotoxic serum nephritis, induced by passive transfer…Abstract Number: 2852 • 2018 ACR/ARHP Annual Meeting
Excessive Formation of Neutrophil Extracellular Traps: Different Role in the Pathogenesis of ANCA-Associated Vasculitis and Systemic Lupus Erythematosus
Background/Purpose: ANCA-associated vasculitis (AAV) and systemic lupus erythematosus (SLE) both cause glomerulonephritis with pauci-immune and full-house immunofluorescence patterns, respectively. Although AAV and SLE are clinically…Abstract Number: 2853 • 2018 ACR/ARHP Annual Meeting
A Protective Langerhans Cell-Keratinocyte Axis That Is Dysfunctional in Photosensitivity
Background/Purpose: Photosensitivity, or skin sensitivity to ultraviolet radiation (UVR), is a feature of lupus erythematosus (LE) and other autoimmune conditions. Photosensitive lesions can be disfiguring…Abstract Number: 2854 • 2018 ACR/ARHP Annual Meeting
Majeed Syndrome Causing LPIN2 mutations May Prevent Bone “Healing” By Rendering M2 Macrophage Proinflammatory
Background/Purpose: To study the mechanism that leads to bone inflammation in a 4-year old patient of mixed Puerto Rican and African-American background who presented with…Abstract Number: 2855 • 2018 ACR/ARHP Annual Meeting
Expanding the Phenotype: New Variant in the IL1RN-Gene Associated with Late Onset and Atypical Presentation of Dira
Background/Purpose: Deficiency of the Interleukin-1 receptor antagonist (DIRA) is an autoinflammatory disease of infancy characterized by severe systemic inflammation with bone and skin involvement. This…Abstract Number: 2856 • 2018 ACR/ARHP Annual Meeting
Do Patients with Moderate or High Disease Activity Escalate RA Therapy According to Treat-to-Target Principles? Results from the Acr’s RISE Registry
Background/Purpose: Routine measurement of RA disease activity and adjustment of drug therapy to attain remission or low disease activity is recommended by the ACR and…Abstract Number: 2857 • 2018 ACR/ARHP Annual Meeting
An Electronic Audit, Reporting, and Data Correction System Improves the Quantity and Quality of Observational Data Collected for US Veterans Enrolled in the Veterans Affairs Rheumatoid Arthritis Registry
Background/Purpose: The Veterans Affairs (VA) Rheumatoid Arthritis (RA) (VARA) registry is an observational cohort study of US Veterans with RA at 11 VA Medical…Abstract Number: 2858 • 2018 ACR/ARHP Annual Meeting
Gaps in Patient Safety Performance before Treatment with Biologic Disease-Modifying Antirheumatic Drugs or Tofacitinib in a Large Academic Healthcare System
Background/Purpose: Treatment with biologic disease-modifying antirheumatic drugs (DMARDs) and tofacitinib confer increased risk of life-threatening infections, including reactivation of latent tuberculosis infection (LTBI), hepatitis B…Abstract Number: 2859 • 2018 ACR/ARHP Annual Meeting
Do Preventive Cardiology Consults Versus Usual Care Improve Cardiovascular Risk Factor Assessment and Management in Patients with Rheumatoid Arthritis?
Background/Purpose: Rheumatoid arthritis (RA) patients have around 50% increased risk of cardiovascular disease (CVD). Both traditional and RA-specific cardiovascular (CV) risk factors contribute to the…Abstract Number: 2860 • 2018 ACR/ARHP Annual Meeting
Disease Activity and Its Measurement in Patients with RA across the U.S.: Data from the Rheumatology Informatics System for Effectiveness (RISE) Registry
Background/Purpose: Although national quality measures promote the measurement of disease activity (DA) in RA, the burden of DA in a population-based sample of RA patients…Abstract Number: 2861 • 2018 ACR/ARHP Annual Meeting
Clinical Laboratory Telephone Communication Outreach to Rheumatology Patients Improves Guideline-Concordant Timeliness of Monitoring of Conventional and Biologic Disease-Modifying Anti-Rheumatic Drugs (DMARDs)
Background/Purpose: The American College of Rheumatology has published guidelines for laboratory monitoring of conventional DMARDs (cDMARDs). At Kaiser Permanente Colorado (KPCO), although most patients eventually…
ACR Meeting Abstracts